Synthetic Biologics Inc (NYSEAMERICAN:SYN) saw a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 172,100 shares, an increase of 66.8% from the September 30th total of 103,200 shares. Based on an average daily volume of 83,300 shares, the days-to-cover ratio is presently 2.1 days. Currently, 1.1% of the shares of the company are sold short.
NYSEAMERICAN:SYN opened at $0.43 on Thursday. Synthetic Biologics has a 52-week low of $0.37 and a 52-week high of $0.91.
Synthetic Biologics (NYSEAMERICAN:SYN) last posted its quarterly earnings data on Monday, November 4th. The company reported ($0.31) earnings per share (EPS) for the quarter.
Synthetic Biologics Company Profile
Synthetic Biologics, Inc, a clinical stage company, focuses developing therapeutics designed to preserve the microbiome to protect and restore the health of patients in the United States. Its lead product candidates include SYN-004 that is in Phase III clinical trial designed to protect the gut microbiome from the effects of commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients.
Further Reading: Dividend Yield
Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.